Glioblastoma
889
157
249
353
Key Insights
Highlights
Success Rate
76% trial completion
Published Results
152 trials with published results (17%)
Research Maturity
353 completed trials (40% of total)
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 59/100
12.4%
110 terminated out of 889 trials
76.2%
-10.3% vs benchmark
6%
50 trials in Phase 3/4
43%
152 of 353 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 353 completed trials
Clinical Trials (889)
Temozolomide With or Without Veliparib in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
Sonocloud-9 in Association With Carboplatin Versus Standard-of-Care Chemotherapies (CCNU or TMZ) in Recurrent GBM
A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma
The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Treatment Satisfaction in Cancer Patients Living in the Florida Panhandle and Surrounding Areas
Positron Emission Tomography/Computed Tomography (PET/CT) Imaging in Patients Diagnosed With a Glioma
Short Course Radiotherapy for the Treatment of Patients With Glioblastoma, SAGA Study
Phase I Trial of DNA-PK Inhibitor (PEPOSERTIB ) in Combination With Radiation and Adjuvant Temozolomide in Newly Diagnosed MGMT Unmethylated and Recurrent Glioblastoma
A Phase 1 Safety and Dose Finding Study of GLIX1 in Adults With Recurrent or Progressive High-grade Glioma
Ruxolitinib With Radiation and Temozolomide Compared to Radiation and Temozolomide for Newly Diagnosed Glioblastoma
Assessment of Optune Therapy for Patients With Newly Diagnosed Glioblastoma Using Advanced MRI
PLX038 in Primary Central Nervous System Tumors Containing MYC or MYCN Amplifications
Characterization of the Blood-Brain Barrier in High-Grade Glioma Through Immunohistochemical, Transcriptional, Fluorescein and Radiological Analyses
Phase II Study of BKM120 for Subjects With Recurrent Glioblastoma
A Trial of Belzutifan (PT2977, MK-6482) Tablets In Patients With Advanced Solid Tumors (MK-6482-001)
EF-41/KEYNOTE D58: Phase 3 Study of Optune Concomitant With Temozolomide Plus Pembrolizumab in Newly Diagnosed Glioblastoma
CART-EGFR-IL13Ra2 in Newly Diagnosed GBM Following Initial Radiotherapy
A Phase I/II Study of IVONESCIMAB in Recurrent Glioblastoma
ERAS-801 for the Treatment of Resectable and Progressive or Recurrent or Elderly Newly Diagnosed IDH Wildtype Grade IV Glioblastoma or Gliosarcoma With an EGFR Amplification or Mutation, ERAS801-SARG Trial
Survivin-Targeted Dendritic Cell (DC) Cell Injection for Newly Diagnosed Glioblastoma
Customized Neuro-Imaging Referenced Symptom Video for the Reduction of Patient and Caregiver Anxiety Around Radiation Treatment for Brain Tumors